BetterLife Pharma Files December 2024 6-K Report

Ticker: BETRF · Form: 6-K · Filed: Dec 31, 2024 · CIK: 1464165

Sentiment: neutral

Topics: reporting, foreign-private-issuer, corporate-history

Related Tickers: BETRF

TL;DR

BetterLife Pharma (BETRF) filed its Dec 2024 6-K, confirming 20-F annual report filings.

AI Summary

BetterLife Pharma Inc. filed a Form 6-K for the month of December 2024, reporting as a foreign private issuer. The company, formerly known as Pivot Pharmaceuticals Inc. and Neurokine Pharmaceuticals Inc., is incorporated in A1 and has its principal executive offices in Vancouver, BC. The filing indicates they will file annual reports under Form 20-F.

Why It Matters

This filing provides routine updates for BetterLife Pharma Inc. as a foreign private issuer, informing investors about their reporting status and corporate history.

Risk Assessment

Risk Level: low — This is a routine filing for a foreign private issuer and does not contain significant new financial or operational information.

Key Players & Entities

FAQ

What is the primary purpose of this Form 6-K filing?

This Form 6-K is a Report of Foreign Private Issuer filed pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934, for the month of December 2024.

What is BetterLife Pharma Inc.'s principal executive office address?

The principal executive office is located at 1275 West 6th Avenue, #300, Vancouver, BC V6H 1A6.

Does BetterLife Pharma Inc. file annual reports under Form 20-F or Form 40-F?

The filing indicates that BetterLife Pharma Inc. files annual reports under cover of Form 20-F.

What were BetterLife Pharma Inc.'s former company names?

BetterLife Pharma Inc. was formerly known as Pivot Pharmaceuticals Inc. and Neurokine Pharmaceuticals Inc.

When did the company change its name from Pivot Pharmaceuticals Inc.?

The date of the name change from Pivot Pharmaceuticals Inc. was April 17, 2015.

Filing Stats: 357 words · 1 min read · ~1 pages · Grade level 12.8 · Accepted 2024-12-31 14:15:57

Filing Documents

Management's discussion and analysis

Management's discussion and analysis 99.2

Financial statements

Financial statements 99.3 CEO certification 99.4 CFO certification 99.5 Material Change Report dated December 30, 2024 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934 , the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BETTERLIFE PHARMA INC. Date: December 31, 2024 By: /s/ Moira Ong Name: Moira Ong Title: Chief Financial Officer 3

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing